1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Is Dexcom Piecing Together An Artificial Pancreas Puzzle With TypeZero?

 
• By Tina Tan

The leader in continuous glucose monitoring, Dexcom has acquired TypeZero Technologies, a specialist in developing algorithms for artificial pancreas systems. Does Dexcom have its sights on expanding beyond glucose monitoring and into insulin delivery, and building an artificial pancreas of its own?

Diabetes

Dexcom Inc. has gained a new diabetes management platform with the acquisition of TypeZero Technologies, a developer of algorithms that orchestrate insulin dosing with blood glucose monitoring data in an artificial pancreas (AP) system. Terms of the acquisition were not disclosed.

TypeZero's InControl platform emerged from the labs of the University of Virginia's Center for Diabetes Technology. It features a smartphone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Medicare’s TCET Pathway Wins Acclaim From Early Users, Even As ‘Messy Middle’ Persists

 
• By Brian Bossetta

Some of the first manufacturers to receive Medicare coverage for their breakthrough devices through the Transitional Coverage for Emerging Technologies pathway praise CMS’ engagement and timelines in the process, despite some challenges around post-launch data collection.

AdvaMed Warns Of Challenges With Remote Devices While Noting Their Potential

 
• By Brian Bossetta

Though the advance of remote medical device technology allows for better at-home care, it comes with challenges and risks, says AdvaMed, which has published a safety bulletin guiding stakeholders on the operation of remote devices.

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By Marion Webb

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Dexcom Pushes Forward With R&D Growth, New Devices Amid Scrutiny And Shake-Up

 
• By Marion Webb

Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.

More from Device Area

Medicare’s TCET Pathway Wins Acclaim From Early Users, Even As ‘Messy Middle’ Persists

 
• By Brian Bossetta

Some of the first manufacturers to receive Medicare coverage for their breakthrough devices through the Transitional Coverage for Emerging Technologies pathway praise CMS’ engagement and timelines in the process, despite some challenges around post-launch data collection.

HistoSonics Closed $250M Funding To Expand, But IPO ‘Not Immediate Priority,’ Says CEO

 
• By Marion Webb

The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.

Successful Diagnostics Alter Clinical Pathways, Says NHS Foundation Trust Leader

 
• By Natasha Barrow

Evidence-based testing in real clinical settings and diagnostics tailored to community needs are crucial adoption success factors for new IVDs, Michael Wright, joint medical director at Newcastle Hospitals NHS Foundation Trust, told Medtech Insight at a regional UK meeting.